Cofactor Genomics
Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
The firm highlighted a new study exploring immune-related gene expression in ovarian cancer and gave an update on its lead diagnostic candidate for head and neck tumors.
Cofactor Genomics, UCSD Partner on Metastatic Head, Neck Cancer Study
The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.
The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.
Cofactor Genomics Inks Pilot Study Deal for Immune Profiling Kit Evaluation
Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.